DarioHealth reports Aon savings review: what it means for DarioHealth stock

Published on 10/21/2026 at 02:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Aon reviewed 17 studies on October 6, 2026. The 2.5 to 7.2 percent savings estimate frames DarioHealth stock for investors and analysts alike.

Commercial evidence and financial results

Aon reviewed 17 studies for DarioHealth on October 6, 2026.
DarioHealth reported USD 5.18 million in second-quarter 2026 revenue and a USD 7.92 million net loss.
DarioHealth had a USD 40.0 million market capitalization as of October 20, 2026.

DRIO, US23725P3082, Illustration mit AI erstellt.

DarioHealth (US23725P3082) reported an Aon review estimating 2.5 to 7.2 percent annual healthcare-cost savings on October 6, 2026, according to PR Newswire. The review gives DarioHealth stock a commercial-growth narrative, but its second-quarter figures show the financial pressure that still frames the story.

Aon review covers 17 studies

PR Newswire said Aon evaluated 17 studies covering cardiometabolic, musculoskeletal and behavioral health programs. Aon estimated that direct physician access and multi-condition management could add 1.6 to 2.8 percentage points to healthcare-cost savings, creating a potential total of 10 percent annually. The review was limited to materials identified or provided by Dario, and Aon did not independently verify the underlying data.

What does the review mean for revenue?

The commercial claim sits beside a second-quarter 2026 revenue figure of USD 5.18 million and a net loss of USD 7.92 million, according to MarketBeat. Revenue was below the USD 5.92 million consensus estimate, while earnings per share of USD -0.85 exceeded the USD -1.22 consensus estimate by USD 0.37. Gross margin reached 62 percent in the quarter.

Three dated steps in the strategy

On July 16, 2026, DarioHealth announced a Fortune 50 employer contract covering more than 100,000 eligible employees. On September 17, 2026, the company announced a New Jersey health-plan contract representing 1.5 million covered lives. On October 6, 2026, it published the Aon review with its 2.5 to 7.2 percent annual savings estimate.

Next reporting date points to November

MarketBeat lists November 12, 2026, for DarioHealth's third-quarter results. That release should show whether the contracts and clinical-cost evidence are translating into reported revenue.

Commercial promise meets financial strain

DarioHealth combines connected devices, digital engagement, data analysis and provider-backed care for chronic conditions including diabetes, hypertension, weight management, musculoskeletal needs and behavioral health, according to the October 6, 2026 company release. The company had a market capitalization of USD 40.0 million as of October 20, 2026, making the conversion of contracted opportunities into revenue a central measure for the stock.